Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Myeloid Leukemia, Philadelphia Positive: early-phase trial registry

1 of 1 indexed Myeloid Leukemia, Philadelphia Positive trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Myeloid Leukemia, Philadelphia Positive: 1 US clinical trial tracked, 1 recruiting.

Myeloid Leukemia, Philadelphia Positive is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition myeloid-leukemia-philadelphia-positive

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Myeloid Leukemia, Philad (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Myeloid Leukemia, Philadelphia Positive

Myeloid Leukemia, Philadelphia Positive lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myeloid Leukemia, Philadelphia Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myeloid Leukemia, Philadelphia Positive is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Myeloid Leukemia, Philadelphia Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Asciminib Adult formulation group Drug
1 trials
Asciminib Pediatric formulation group Drug
1 trials

US sites by state

Facility locations filed on Myeloid Leukemia, Philadelphia Positive trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
Mississippi 1 trials
Massachusetts 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myeloid Leukemia, Philadelphia Positive page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Myeloid Leukemia, Philadelphia Positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Novartis Pharmaceuticals sponsors the most Myeloid Leukemia, Philadelphia Positive trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Leukemia, Philadelphia Positive condition card totals 1 registered trials; most-linked intervention Asciminib Adult formulation group; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.